Senior Lecturer in Epidemiology
Epidemiology and Mathematical Modelling
I am an infectious disease epidemiologist, based in the Disease Dynamics Unit. I obtained my first degree in Human Sciences from the University of Oxford before completing an MSc in Communicable Disease Epidemiology at the London School of Hygiene and Tropical Medicine. My PhD (University of London, 2004), based jointly at LSHTM and the Health Protection Agency, examined the impact of vaccination against group C meningococcal (MenC) disease. I spent 7 years at the University of Bristol before moving to Cambridge in 2013. I hold honorary positions at the University of Bristol and Public Health England.
Subject groups/Research projects
My research concentrates on understanding the epidemiology of vaccine-preventable diseases and the impact of immunisation. The majority of my work is on meningococcal infection, but I am also involved in research on pneumococcus, rotavirus, group B streptococcus and human papillomavirus. I use a range of methods including analysis of large databases, systematic reviews, prospective clinical/ field studies, health economics, seroprevalence studies and mathematical modelling. I am most interested in applying these methods to research questions of direct relevance for vaccine policy.
I currently work with the African Meningococcal Carriage Consortium (MenAfriCar), a global research effort to study how meningococcal meningitis is spread in Africa, and to document the impact of a new meningitis vaccine (MenAfriVac) on reducing transmission. Our recent study in Chad has shown that MenAfriVac has had a dramatic impact on disease and carriage in a region experiencing a group A epidemic.
I am an honorary epidemiologist in the Immunisation Department, Public Health England and an honorary Senior Lecturer in the School of Social and Community Medicine at the University of Bristol.
I have supervised 4 PhD students to successful completion at the University of Bristol.
Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating the cost-effectiveness of universal ‘MenB’ (Bexsero) vaccination in England: a modelling study. BMJ 2014 Published online 10/10/2014
Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron M, Ferman F, Page A-L, Djingarey M, Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Caugant DA, Chandramohan D, Hassan-King M, Manigart O, Nascimento M, Woukeu A, Trotter C, Stuart JM, Maiden MCJ, Greenwood B. The impact of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad. Lancet 2014.383:40-7
Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013;31(23):2638-46
Irving T, Blyuss K, Colijn C, Trotter CL. Modelling meningococcal meningitis in the African meningitis belt. Epidemiol & Infect 2012 May;140(5):897-905.
Rozenbaum M, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Cost-effectiveness of vaccinating risk groups in England against invasive pneumococcal disease using the 13 valent pneumococcal vaccine: an economic analysis. BMJ. 2012 345:e6879
Christensen H, May MT, Bowen L, Hickman M, Trotter CL. A systematic review of meningococcal carriage by age. Lancet Infect Dis 2010, 10:853-61
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009. 27(S2):B51-B63.
Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland K, Goldblatt D, Hombach J, Kieny M-P, on behalf of the SAGE subgroup.. Optimising the use of conjugate vaccines for Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008, 26(35):4434-45.
Trotter CL, Greenwood BM. Meningococcal carriage studies in the African meningitis belt: a review. Lancet Infect Dis. 2007; 7(12): 797-803